

# Mihai Gheorghiane

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8672586/publications.pdf>

Version: 2024-02-01

166  
papers

17,142  
citations

31976

53  
h-index

14208

128  
g-index

169  
all docs

169  
docs citations

169  
times ranked

15229  
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. <i>Heart Failure Reviews</i> , 2021, 26, 1529-1529.	3.9	1
2	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 942-951.	1.6	17
3	Assessment and management of coronary artery disease in kidney and pancreas transplant candidates. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 51-58.	1.5	12
4	Medication dosing for heart failure with reduced ejection fraction—opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019, 21, 286-296.	7.1	57
5	Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?. <i>Journal of Cardiac Failure</i> , 2018, 24, 112-114.	1.7	7
6	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 597-607.	3.9	6
7	Lessons learned in acute heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 630-641.	7.1	33
8	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 281-291.	7.1	33
9	Past, present, and future of acute heart failure clinical trials—a high-risk population in search of a strategy. <i>European Journal of Heart Failure</i> , 2018, 20, 839-841.	7.1	4
10	Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , 2018, 36, 63-72.	2.2	12
11	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 677-686.	7.1	21
12	A new educational program in heart failure drug development. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 411-421.	1.5	8
13	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 783-792.	1.7	11
14	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1601-1610.	7.1	27
15	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	6
16	Mobile health applications in cardiovascular research. <i>International Journal of Cardiology</i> , 2018, 269, 265-271.	1.7	23
17	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303.	1.7	9
18	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	2.8	193

#	ARTICLE	IF	CITATIONS
19	Is there a clinically meaningful difference in patient reported dyspnea in acute heart failure? An analysis from URGENT Dyspnea. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 300-307.	1.6	12
20	Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 870-872.	7.1	2
21	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <sc>ASTRONAUT</sc> trial. European Journal of Heart Failure, 2017, 19, 552-562.	7.1	23
22	Patient-reported outcomes in the <sc>SOLuble</sc> guanylate Cyclase <sc>stimuloR</sc> in <sc>heArT failurE patientS</sc> with <sc>PRESERVED</sc> ejection fraction (<sc>SOCRATESâ€PRESERVED</sc>) study. European Journal of Heart Failure, 2017, 19, 782-791.	7.1	84
23	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimuloR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	2.2	285
24	Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Failure Reviews, 2017, 22, 263-277.	3.9	18
25	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. Canadian Journal of Cardiology, 2017, 33, 768-776.	1.7	11
26	Reassessing Phase II Heart Failure Clinical Trials. Circulation: Heart Failure, 2017, 10, .	3.9	14
27	Mitochondrial function as a therapeutic target in heart failure. Nature Reviews Cardiology, 2017, 14, 238-250.	13.7	525
28	Protein turnover in the failing heart: an ever-changing landscape. European Journal of Heart Failure, 2017, 19, 1218-1221.	7.1	2
29	Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Failure, 2017, 4, 402-408.	3.1	50
30	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. International Journal of Cardiology, 2017, 248, 414-420.	1.7	4
31	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2017, 2, 995.	6.1	164
32	Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement. European Journal of Heart Failure, 2017, 19, 1424-1426.	7.1	9
33	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	47
34	Clinical profiles in acute heart failure: one size fits all or not at all?. European Journal of Heart Failure, 2017, 19, 1255-1257.	7.1	3
35	Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	19
36	Novel Endpoints for Heart Failure Clinical Trials. Current Heart Failure Reports, 2017, 14, 210-216.	3.3	12

#	ARTICLE	IF	CITATIONS
37	Clinical trials in acute heart failure: beginning of the end or end of the beginning?. <i>European Journal of Heart Failure</i> , 2017, 19, 1358-1360.	7.1	5
38	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy. <i>Circulation Research</i> , 2017, 120, 332-340.	4.5	144
39	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451.	2.0	38
40	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 122.	3.0	27
41	Moving away from symptomsâ€based heart failure treatment: misperceptions and real risks for patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 350-352.	7.1	23
42	Serum chloride in heart failure: a salty prognosis. <i>European Journal of Heart Failure</i> , 2016, 18, 669-671.	7.1	12
43	Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. <i>European Journal of Heart Failure</i> , 2016, 18, 1190-1192.	7.1	6
44	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2016, 18, 185-191.	7.1	13
45	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016, 214, 16-18.	1.7	2
46	In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 580-588.	4.1	10
47	Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender. <i>Clinical Research in Cardiology</i> , 2016, 105, 421-431.	3.3	17
48	Digoxin for Worsening Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 365-367.	4.1	6
49	Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1575-1589.	2.8	86
50	Transforming Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	8
51	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016, 18, 54-65.	7.1	73
52	Targeting digoxin dosing to serum concentration: is the bullseye too small?. <i>European Journal of Heart Failure</i> , 2016, 18, 1082-1084.	7.1	5
53	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	2.2	274
54	Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 199.	1.7	38

#	ARTICLE	IF	CITATIONS
55	Partial Adenosine A1 Agonist in Heart Failure. Handbook of Experimental Pharmacology, 2016, 243, 177-203.	1.8	24
56	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	46
57	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. American Journal of Cardiology, 2016, 117, 1144-1150.	1.6	23
58	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. American Journal of Cardiology, 2016, 117, 1845-1850.	1.6	11
59	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Failure Reviews, 2016, 21, 95-102.	3.9	55
60	Trends in Heart Failure Clinical Trials From 2001 to 2012. Journal of Cardiac Failure, 2016, 22, 171-179.	1.7	22
61	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	15
62	Utility of positron emission tomography for drug development for heart failure. American Heart Journal, 2016, 175, 142-152.	2.7	9
63	Global variation in clinical profile, management, and postdischarge outcomes among patients hospitalized for worsening chronic heart failure: findings from the <sc>ASTRONAUT</sc> trial. European Journal of Heart Failure, 2015, 17, 591-600.	7.1	58
64	Letter by Abu Daya et al Regarding Article, "Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction, Contributions of Collagen and Titin". Circulation, 2015, 132, e248.	1.6	0
65	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. European Journal of Heart Failure, 2015, 17, 760-763.	7.1	16
66	In-hospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	7.1	60
67	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the <sc>EVEREST</sc> trial. European Journal of Heart Failure, 2015, 17, 1022-1031.	7.1	52
68	Agents with vasodilator properties in acute heart failure: how to design successful trials. European Journal of Heart Failure, 2015, 17, 652-664.	7.1	24
69	Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?. European Journal of Heart Failure, 2015, 17, 875-878.	7.1	14
70	Pulmonary Oedema Therapeutic Targets. Cardiac Failure Review, 2015, 1, 38.	3.0	12
71	Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). American Journal of Cardiology, 2015, 116, 307-312.	1.6	2
72	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2015, 115, 790-796.	1.6	37

#	ARTICLE	IF	CITATIONS
73	Population Risk Prediction Models for Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 438-447.	3.9	69
74	Think Small and Examine the Constituents of Left Ventricular Hypertrophy and Heart Failure: Cardiomyocytes Versus Fibroblasts, Collagen, and Capillaries in the Interstitium. <i>Journal of the American Heart Association</i> , 2015, 4, e002491.	3.7	11
75	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	174
76	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , 2015, 12, 220-229.	13.7	238
77	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	4.1	265
78	Contemporary Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 826-831.	3.9	34
79	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015, 116, 1304-1310.	1.6	5
80	Trends in characteristics of cardiovascular clinical trials 2001-2012. <i>American Heart Journal</i> , 2015, 170, 263-272.e2.	2.7	26
81	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. <i>European Journal of Heart Failure</i> , 2015, 17, 735-742.	7.1	73
82	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	2.7	20
83	Digoxin use in atrial fibrillation: a critical reappraisal. <i>Lancet, The</i> , 2015, 385, 2330-2332.	13.7	13
84	Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2038-2047.	2.8	49
85	Targeting the Heart in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 661-669.	4.1	50
86	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	7.4	288
87	A roadmap to inpatient heart failure management. <i>Journal of Cardiology</i> , 2015, 65, 26-31.	1.9	4
88	Revisiting Cardiac Injury During Acute Heart Failure: Further Characterization and a Possible Target for Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 141-146.	1.6	3
89	Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2015, 131, 269-279.	1.6	763
90	Hemoconcentration-guided Diuresis in Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 1154-1159.	1.5	43

#	ARTICLE	IF	CITATIONS
91	Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. JAMA - Journal of the American Medical Association, 2014, 312, 789.	7.4	58
92	Molecular and Cellular Basis of Viable Dysfunctional Myocardium. Circulation: Heart Failure, 2014, 7, 680-691.	3.9	46
93	Management of Comorbid Diabetes Mellitus and Worsening Heart Failure. JAMA - Journal of the American Medical Association, 2014, 311, 2379.	7.4	47
94	Therapeutic Targets in Heart Failure. Journal of the American College of Cardiology, 2014, 63, 2188-2198.	2.8	124
95	The Global Health and Economic Burden of Hospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133.	2.8	1,640
96	Developing Therapies for Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	4.1	267
97	The Burden of Acute Heart Failure on U.S. Emergency Departments. JACC: Heart Failure, 2014, 2, 269-277.	4.1	176
98	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0 0 OrgBT /Over 10 TF		
99	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 401-408.	3.9	34
100	Clinical Effectiveness of CRT and ICD Therapy in Heart Failure Patients by Racial/Ethnic Classification. Journal of the American College of Cardiology, 2014, 64, 797-807.	2.8	32
101	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	2.2	304
102	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). American Journal of Cardiology, 2014, 114, 743-750.	1.6	8
103	Matching Mechanism of Death With Mechanism of Action. Journal of the American College of Cardiology, 2014, 64, 1599-1601.	2.8	24
104	The Use of Digoxin in Patients With Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1823-1832.	2.8	88
105	Performance Matters in Heart Failure. Journal of the American College of Cardiology, 2014, 63, 131-132.	2.8	2
106	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. American Heart Journal, 2014, 168, 142-149.	2.7	34
107	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152.	3.9	48
108	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Failure Reviews, 2013, 18, 107-122.	3.9	51



#	ARTICLE	IF	CITATIONS
109	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2013, 15, 679-689.	7.1	30
110	Hospitalizations for Heart Failure. Heart Failure Clinics, 2013, 9, xi-xii.	2.1	0
111	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. JACC: Heart Failure, 2013, 1, 488-496.	4.1	58
112	Evaluative Framework for Phase II Studies in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2013, 1, 123-126.	4.1	8
113	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. Journal of the American College of Cardiology, 2013, 61, 571-579.	2.8	58
114	Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Heart Failure Clinics, 2013, 9, 285-290.	2.1	37
115	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	3.9	28
116	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1125.	7.4	297
117	Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134.	3.9	118
118	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure, 2013, 15, 551-559.	7.1	75
119	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. European Journal of Heart Failure, 2012, 14, 1056-1066.	7.1	105
120	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Failure Reviews, 2012, 17, 485-509.	3.9	100
121	Medication Dosing in Outpatients With Heart Failure After Implementation of a Practice-Based Performance Improvement Intervention: Findings From IMPROVE HF. Congestive Heart Failure, 2012, 18, 9-17.	2.0	69
122	A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes. JAMA - Journal of the American Medical Association, 2011, 305, 1702.	7.4	48
123	Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. American Heart Journal, 2011, 161, 224-232.	2.7	38
124	Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. Journal of Heart and Lung Transplantation, 2011, 30, 218-226.	0.6	30
125	Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure, 2011, 13, 100-106.	7.1	68
126	Improving Postdischarge Outcomes in Patients Hospitalized for Acute Heart Failure Syndromes. JAMA - Journal of the American Medical Association, 2011, 305, 2456.	7.4	41



#	ARTICLE	IF	CITATIONS
127	One step forward, two steps back. <i>Nature Reviews Cardiology</i> , 2011, 8, 72-73.	13.7	6
128	Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. <i>Discovery Medicine</i> , 2011, 12, 141-51.	0.5	14
129	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , 2010, 12, 423-433.	7.1	593
130	Digoxin for the treatment of chronic and acute heart failure syndromes. <i>Acute Cardiac Care</i> , 2009, 11, 83-87.	0.2	21
131	Reconsidering the Role for Digoxin in the Management of Acute Heart Failure Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2146.	7.4	61
132	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article "The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy". <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 335-336.	2.6	0
133	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	2.7	48
134	The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. <i>American Heart Journal</i> , 2009, 158, 437-443.	2.7	13
135	Acute Heart Failure Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 53, 557-573.	2.8	515
136	Introduction. <i>American Journal of Cardiology</i> , 2008, 101, S1-S2.	1.6	2
137	Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2276-2285.	2.8	145
138	Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. <i>European Heart Journal</i> , 2007, 28, 980-988.	2.2	514
139	Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1332.	7.4	757
140	Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial. <i>Archives of Internal Medicine</i> , 2007, 167, 1998.	3.8	300
141	Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment. <i>American Journal of Medicine</i> , 2006, 119, S3-S10.	1.5	339
142	Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia. <i>American Journal of Cardiology</i> , 2006, 97, 1064-1067.	1.6	129
143	Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2217.	7.4	854
144	Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. <i>Circulation</i> , 2006, 113, 2556-2564.	1.6	164

#	ARTICLE	IF	CITATIONS
145	The clinical effects of vasopressin receptor antagonists in heart failure.. Cleveland Clinic Journal of Medicine, 2006, 73, S24-S24.	1.3	10
146	Congestion is an important diagnostic and therapeutic target in heart failure. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 1, S12-24.	1.4	10
147	Introduction to Acute Heart Failure Syndromes. American Journal of Cardiology, 2005, 96, 1-4.	1.6	24
148	The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). American Journal of Cardiology, 2005, 96, 18-25.	1.6	59
149	Pharmacology of New Agents for Acute Heart Failure Syndromes. American Journal of Cardiology, 2005, 96, 68-73.	1.6	54
150	The Challenge of Acute Heart Failure Syndromes. American Journal of Cardiology, 2005, 96, 86-89.	1.6	17
151	Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials. American Journal of Cardiology, 2005, 96, 3-9.	1.6	217
152	Acute Heart Failure Syndromes. Circulation, 2005, 112, 3958-3968.	1.6	690
153	Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure<SUBTITLE>>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2004, 291, 1963.	7.4	603
154	Digoxin in the Management of Cardiovascular Disorders. Circulation, 2004, 109, 2959-2964.	1.6	206
155	Closing statement. American Journal of Medicine, 2004, 116, 89-90.	1.5	0
156	Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2004, 5, 160-2.	0.1	2
157	Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal, 2003, 145, S51-S54.	2.7	43
158	Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). American Heart Journal, 2003, 145, S55-S57.	2.7	5
159	Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. American Heart Journal, 2003, 145, S60-S61.	2.7	9
160	Surrogate end points in heart failure trials. American Heart Journal, 2003, 145, S67-S70.	2.7	18
161	Vasopressin V <sub>2</sub> -Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure. Circulation, 2003, 107, 2690-2696.	1.6	416
162	OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. European Journal of Heart Failure, 2003, 5, 9-12.	7.1	17

#	ARTICLE	IF	CITATIONS
163	Patterns of angiotensinâ€converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. <i>Clinical Cardiology</i> , 1998, 21, 261-268.	1.8	19
164	Chronic Heart Failure in the United States. <i>Circulation</i> , 1998, 97, 282-289.	1.6	721
165	Standards of laboratory practice: cardiac drug monitoring. <i>Clinical Chemistry</i> , 1998, 44, 1096-1109.	3.2	50
166	Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 761-768.	2.6	3